Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study
dc.contributor.author | Koshkin, Vadim S. | |
dc.contributor.author | Henderson, Nicholas | |
dc.contributor.author | James, Marihella | |
dc.contributor.author | Natesan, Divya | |
dc.contributor.author | Freeman, Dory | |
dc.contributor.author | Nizam, Amanda | |
dc.contributor.author | Su, Christopher T. | |
dc.contributor.author | Khaki, Ali Raza | |
dc.contributor.author | Osterman, Chelsea K. | |
dc.contributor.author | Glover, Michael J. | |
dc.contributor.author | Chiang, Ryan | |
dc.contributor.author | Makrakis, Dimitrios | |
dc.contributor.author | Talukder, Rafee | |
dc.contributor.author | Lemke, Emily | |
dc.contributor.author | Olsen, T. Anders | |
dc.contributor.author | Jain, Jayanshu | |
dc.contributor.author | Jang, Albert | |
dc.contributor.author | Ali, Alicia | |
dc.contributor.author | Jindal, Tanya | |
dc.contributor.author | Chou, Jonathan | |
dc.contributor.author | Friedlander, Terence W. | |
dc.contributor.author | Hoimes, Christopher | |
dc.contributor.author | Basu, Arnab | |
dc.contributor.author | Zakharia, Yousef | |
dc.contributor.author | Barata, Pedro C. | |
dc.contributor.author | Bilen, Mehmet A. | |
dc.contributor.author | Emamekhoo, Hamid | |
dc.contributor.author | Davis, Nancy B. | |
dc.contributor.author | Shah, Sumit A. | |
dc.contributor.author | Milowsky, Matthew I. | |
dc.contributor.author | Gupta, Shilpa | |
dc.contributor.author | Campbell, Matthew T. | |
dc.contributor.author | Grivas, Petros | |
dc.contributor.author | Sonpavde, Guru P. | |
dc.contributor.author | Kilari, Deepak | |
dc.contributor.author | Alva, Ajjai S. | |
dc.date.accessioned | 2022-03-07T03:12:30Z | |
dc.date.available | 2023-04-06 22:12:29 | en |
dc.date.available | 2022-03-07T03:12:30Z | |
dc.date.issued | 2022-03-15 | |
dc.identifier.citation | Koshkin, Vadim S.; Henderson, Nicholas; James, Marihella; Natesan, Divya; Freeman, Dory; Nizam, Amanda; Su, Christopher T.; Khaki, Ali Raza; Osterman, Chelsea K.; Glover, Michael J.; Chiang, Ryan; Makrakis, Dimitrios; Talukder, Rafee; Lemke, Emily; Olsen, T. Anders; Jain, Jayanshu; Jang, Albert; Ali, Alicia; Jindal, Tanya; Chou, Jonathan; Friedlander, Terence W.; Hoimes, Christopher; Basu, Arnab; Zakharia, Yousef; Barata, Pedro C.; Bilen, Mehmet A.; Emamekhoo, Hamid; Davis, Nancy B.; Shah, Sumit A.; Milowsky, Matthew I.; Gupta, Shilpa; Campbell, Matthew T.; Grivas, Petros; Sonpavde, Guru P.; Kilari, Deepak; Alva, Ajjai S. (2022). "Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study." Cancer (6): 1194-1205. | |
dc.identifier.issn | 0008-543X | |
dc.identifier.issn | 1097-0142 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/171856 | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | antibody‐drug conjugate | |
dc.subject.other | urinary bladder | |
dc.subject.other | urothelial cancer | |
dc.subject.other | nectin‐4 | |
dc.subject.other | enfortumab vedotin | |
dc.subject.other | bladder cancer | |
dc.title | Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Oncology and Hematology | |
dc.subject.hlbsecondlevel | Public Health | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/171856/1/cncr34057_am.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/171856/2/cncr34057.pdf | |
dc.identifier.doi | 10.1002/cncr.34057 | |
dc.identifier.source | Cancer | |
dc.identifier.citedreference | Teo MY, Ratna N, Regazzi AM, et al. Enfortumab vedotin in FGFR3‐mutated advanced urothelial carcinoma. J Clin Oncol. 2021; 39 ( suppl ): 458. | |
dc.identifier.citedreference | Kim K, Hu W, Audenet F, et al. Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. Nat Commun. 2020; 11: 1975. | |
dc.identifier.citedreference | Hoffman‐Censits JH, Lombardo KA, Parimi V, et al. Expression of nectin‐4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes. Appl Immunohistochem Mol Morphol. 2021; 29: 619 ‐ 625. | |
dc.identifier.citedreference | Hoffman‐Censits JH, Choi W, Lombardo K, et al. Expression of nectin‐4 in bladder cancer with variant histology. J Clin Oncol. 2020; 38 ( suppl ): 546. | |
dc.identifier.citedreference | Tagawa ST, Balar AV, Petrylak DP, et al. TROPHY‐U‐01: a phase II open‐label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum‐based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021; 39: 2474 ‐ 2485. | |
dc.identifier.citedreference | Siefker‐Radtke AO, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma (mUC): long‐term outcomes in BLC2001. J Clin Oncol. 2020; 38: 5015. | |
dc.identifier.citedreference | Balar AV, McGregor BA, Rosenberg JE, et al. EV‐201 cohort 2: enfortumab vedotin in cisplatin‐ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD‐1/PD‐L1 inhibitors. J Clin Oncol. 2021; 39 ( suppl ): 394. | |
dc.identifier.citedreference | Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228 ‐ 247. | |
dc.identifier.citedreference | Harris PA, Taylor R, Thielke R, et al. Research Electronic Data Capture (REDCap)—a metadata‐driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009; 42: 377 ‐ 381. | |
dc.identifier.citedreference | Chu CE, Sjöström M, Egusa EA, et al. Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin. Clin Cancer Res. 2021; 27: 5123. | |
dc.identifier.citedreference | Rosenberg JE, Flaig TW, Friedlander TW, et al. Study EV‐103: preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. J Clin Oncol. 2020; 38 ( suppl ): 441. | |
dc.identifier.citedreference | Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021; 384: 1125 ‐ 1135. | |
dc.identifier.citedreference | Rosenberg JE, O’Donnell PH, Balar AV, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti–programmed death 1/programmed death ligand 1 therapy. J Clin Oncol. 2019; 37: 2592 ‐ 2600. | |
dc.identifier.citedreference | Heath EI, Rosenberg JE. The biology and rationale of targeting nectin‐4 in urothelial carcinoma. Nat Rev Urol. 2021; 18: 93 ‐ 103. | |
dc.identifier.citedreference | Rosenberg J, Sridhar SS, Zhang J, et al. EV‐101: a phase I study of single‐agent enfortumab vedotin in patients with nectin‐4–positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol. 2020; 38: 1041 ‐ 1049. | |
dc.identifier.citedreference | Challita‐Eid PM, Satpayev D, Yang P, et al. Enfortumab vedotin antibody‐drug conjugate targeting nectin‐4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 2016; 76: 3003 ‐ 3013. | |
dc.identifier.citedreference | Balar AV, Castellano D, O’Donnell PH, et al. First‐line pembrolizumab in cisplatin‐ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE‐052): a multicentre, single‐arm, phase 2 study. Lancet Oncol. 2017; 18: 1483 ‐ 1492. | |
dc.identifier.citedreference | Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first‐line treatment in cisplatin‐ineligible patients with locally advanced and metastatic urothelial carcinoma: a single‐arm, multicentre, phase 2 trial. Lancet. 2017; 389: 67 ‐ 76. | |
dc.identifier.citedreference | Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high‐dose‐intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony‐stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001; 19: 2638 ‐ 2646. | |
dc.identifier.citedreference | Rosenberg JE, Hoffman‐Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum‐based chemotherapy: a single‐arm, multicentre, phase 2 trial. Lancet. 2016; 387: 1909 ‐ 1920. | |
dc.identifier.citedreference | Sternberg CN, Yagoda A, Scher HI, et al. M‐VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol. 1988; 139: 461 ‐ 469. | |
dc.identifier.citedreference | Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020; 383: 1218 ‐ 1230. | |
dc.identifier.citedreference | Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second‐line therapy for advanced urothelial carcinoma. N Engl J Med. 2017; 376: 1015 ‐ 1026. | |
dc.identifier.citedreference | von der Maase H, Sengelov L, Roberts JT, et al. Long‐term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23: 4602 ‐ 4608. | |
dc.working.doi | NO | en |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.